2024 AGENDA
6:00 – 9:30 PM | Registration | |
6:00 – 7:00 PM | Welcome Reception | South Ballroom |
7:00 – 9:30 PM | Welcome Dinner Welcome Address: Dr. C. Kollmannsberger, GUTG Chair Keynote Speaker: |
South Ballroom |
Saturday, April 20th, 2024
All Sessions include 25% of Time for Question Periods and Audience Participation
7:00 – 8:00 AM | Breakfast | Kerrisdale Ballroom |
8:00 – 8:05 AM | Welcome Day 1 | Dr. Krista Noonan – GUTG Systemic Chair South Ballroom |
Prostate Session 1: Localized PC
Session Chairs: Dr. Cal Andreou, Dr. Ryan Urban, Dr. Josh Wiesenthal,
8:00 – 8:20 AM | Localized High Risk Prostate Cancer: Is There a Role for Neoadjuvant Treatment? | Dr. Miles Mannas |
8:20 – 8:40 AM | Panel: Multidisciplinary Care for High Risk Localized Prostate Cancer: Local Treatment and Adjuvant Therapy | Dr. Mira Keyes, Dr. Nathan Wong |
8:40 – 9:00 AM | Non-Metastatic Biochemical Recurrence After Local Therapy for Prostate Cancer: Novel Treatment Options and Multidisciplinary Care | Dr. Michael Peacock |
9:00 – 9:20 AM | Management of ARPis: Toxicity Management and Practical Application | Dr. Sunil Parimi |
9:20 – 9:40 AM | Update on Genomic Testing | Dr. Alex Wyatt |
Special Session: Radiopharmaceutical Treatments for Prostate Cancer
Session Chairs: Dr. Param Bains, Dr. James Curtis, Dr. Stacy Miller
9:40 – 9:55 AM | PSMA PET: Indications and Future Use | Dr. Patrick Martineau |
9:55 – 10:10 AM | Delivery / Management – State of Affairs in BC | Dr. Don Wilson |
10:10 – 10:15 AM | Panel Discussion and Q&A Period | Dr. Patrick Martineau, Dr. Don Wilson |
10:15 – 10:30 AM | Health Break & Networking |
RCC Session
Session Chairs: Dr. Soha Atalla, Dr. Samrad Ghavimi, Dr. Ed Hardy
10:30 – 10:55 AM | DEBATE: Adjuvant Pembro in High Risk RCC: Is There an Ideal Patient? – Yes, All Patients Should Be Treated – No, Only Selected Patients Should Be Treated |
Yes – Dr. Simon Yu No – Dr. Adam Fundytus |
10:55 – 11:15 AM | IO-Refractory RCC: Management Options | Dr. Aleksi Suo |
11:15 – 11:35 AM | Pathologic and Molecular Classification of RCC: Update on New Subtypes | Dr. Gang Wang |
11:35 – 11:55 AM | Hereditary Kidney Cancer Syndromes | Dr. Daniel Araujo |
11:55 – 12:15 PM | First Line Treatment of Non-Clear Cell RCC: Therapeutic Choices and Management | Dr. Daygen Finch |
12:15 – 1:00 PM | Lunch / Networking / Exhibition | Kerrisdale Ballroom |
1:00 – 1:20 PM | Special Session: Future of Cancer Care in BC | Dr. Kim Chi |
1:20 – 1:30 PM | Question & Answer Period |
Testis / Penile Cancer Session
Session Chairs: Dr. Iain McAuley, Dr. Jesse Shustik, Dr. Justin Owen
1:30 – 1:50 PM | Management of Postchemotherapy Residual Masses: Urology | Dr. Matthew Ho |
1:50 – 2:10 PM | Management of Postchemotherapy Residual Masses: Thoracic Oncology | Dr. Alex Lee |
Penile Cancer
2:10 – 2:25 PM | Surgery | Dr. Nathan Wong |
2:25 – 2:40 PM | Radiation Oncology | Dr. Juanita Crook |
2:40 – 2:55 PM | Medical Oncology | Dr. Michael Humphreys |
2:55 – 3:10 PM | Discussions | Dr. Nathan Wong, Dr. Juanita Crook, Dr. Michael Humphreys |
3:10 – 3:15 PM | Closing Remarks for Day 1 | Dr. Nathan Hoag, BCUS Chair |
7:00 PM | Dinner | Kerrisdale Ballroom |
7:15 PM | Keynote Lecture | Speaker TBD |
Sunday, April 21st, 2024
All Sessions include 25% of Time for Question Periods and Audience Participation
7:00 – 8:00 AM | Breakfast | Central Foyer |
8:00 – 8:05 AM | Welcome | Dr. Jack Zheng – GURG RT Chair South Ballroom |
Bladder Cancer Session
Session Chairs: Dr. Alym Abdulla, Dr. Ardashes Avanessian, Dr. David Kim
8:05 – 8:25 AM | Non-Muscle Invasive Bladder Cancer: Are We Making Progress? | Dr. Brian Yang |
8:25 – 8:45 AM | PANEL: Bladder Preservation/Active Surveillance After Neoadjuvant Therapy in MIBC | Panelists: Dr. Marie-Pier St-Laurent & TBD |
8:45 – 9:05 AM | DEBATE: EV-Pembro / Cis-Gem-Nivo as First Line Treatment for Cis-Eligible Patient: What is the Preferred Treatment for Cisplatin Eligible, Cisplatin-Ineligible and Platinum Ineligible?
– EV/Pembro for All |
EV/Pembro: Dr. Richard Gagnon Cis/Gem/Nivo: |
9:05 – 9:25 AM | Second Line Treatment Post Progression on EV-Pembro | Dr. Jean-Michel Lavoie |
9:25 – 9:45 AM | Is There a Role for Radiation in Oligometastatic / Locally Recurrent UC? | Dr. Tina Zhang |
9:45 – 10:05 AM | Appropriate Peri-Operative Systemic Treatment of Non-Urothelial Bladder Cancers | Dr. Bernie Eigl |
Special Session
Session Chair: Dr. Chris Hoag
10:05 – 10:25 AM | Surgical Quality Assurance for Cancer Care with an Emphasis on GU Cancers | Dr. Carl Brown |
10:25 – 10:50 AM | Health Break / Networking / Exhibition / Check-out | Central Foyer |
Prostate Cancer Session 2: mCRPC
Session Chairs: Dr. Andrew Bang, Dr. Jaco Fourie, Dr. Jeff McCracken
10:50 – 11:10 AM | Targeting the AR in Metastatic PC: Is it Still a Target? | Dr. Lucia Nappi |
11:10 – 11:30 AM | mCRPC: Treatment Sequencing in the Era of Radioligand Therapies and PARP Inhibitor Combinations | Dr. Jasna Deluce |
11:30 – 11:50 AM | Metastatic Prostate Cancer: Novel Targets and Therapeutic Options on the Horizon | Dr. Corinne Maurice-Dror |
11:50 – 12:10 PM | Primary RT for Metastatic Prostate Cancer (PEACE-1 and Longer-Term STAMPEDE Data): Indication and Timing | Dr. Hamid Raziee |
12:10 – 12:15 PM | BCGU Conference Closing Remarks | Dr. Christian Kollmannsberger, GUTG Chair |
Non-Accredited:
Special Session – GU Biobank
Session Chairs: Dr. Corinne Maurice-Dror, Dr. Lucia Nappi, Dr. Alex Wyatt
12:30 – 12:35 PM | RCA to Improve miR371 Detection in Patients with Early Stage GCT | Dr. Andy Jia |
12:35 – 12:40 PM | Biosensor Technology to Predict Tumor Recurrence in Patients With Early GCT | Dr. Sajjad Janfaza |
12:40 – 12:45 PM | Circulating miRNAs Analysis to Predict Immune Response in mRCC Patients | Dr. Guliz Ozgun |
12:45 – 12:50 PM | Prediction of Plasma ctDNA Fraction and Prognostic Implications of Liquid Biopsy in Advanced Prostate Cancer | Dr. Cameron Herberts |
12:50 – 12:55 PM | ctDNA-FGFR Status as a Predictive Biomarker for FGFR Targeted Therapy in Urothelial Cancer | Dr. Gillian Vanderkerkhove |
12:55 – 1:00 PM | The Prevalence of Clonal Hematopoiesis in Metastatic Genitourinary Cancers | Dr. Asli Munzur |
1:00 – 1:45 PM | Discussion and Future Directions |